

Ignace Vergote

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6027499/publications.pdf>

Version: 2024-02-01

396
papers

33,748
citations

8181

76
h-index

4645

170
g-index

408
all docs

408
docs citations

408
times ranked

24995
citing authors

#	ARTICLE	IF	CITATIONS
1	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	2.8	8
2	European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. <i>Annals of Oncology</i> , 2022, 33, 276-287.	1.2	68
3	Clear cell carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 2022, 164, 658-666.	1.4	23
4	Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 753-760.	2.5	3
5	Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. <i>Gynecologic Oncology</i> , 2022, 164, 254-264.	1.4	51
6	Survival with Cemiplimab in Recurrent Cervical Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 544-555.	27.0	182
7	The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2022, 33, 593-601.	1.2	10
8	Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study. <i>Cancers</i> , 2022, 14, 1780.	3.7	4
9	Mitigation and management strategies for ocular events associated with tisotumab vedotin. <i>Gynecologic Oncology</i> , 2022, 165, 385-392.	1.4	20
10	Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 14-22.	1.4	14
11	Ten years of live surgical broadcast at CharitÄ©-MAYO conferences (2010â€“2019): a systematic evaluation of the surgical outcome. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003173.	2.5	2
12	Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse Model. <i>Pharmaceutics</i> , 2022, 14, 687.	4.5	4
13	Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer. <i>Npj Genomic Medicine</i> , 2022, 7, 30.	3.8	4
14	Importance of pathological review of gestational trophoblastic diseases: results of the Belgian Gestational Trophoblastic Diseases Registry. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 740-745.	2.5	5
15	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3053-3065.	7.0	26
16	Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5571-5571.	1.6	2
17	Role of cytoreductive surgery for the second ovarian cancer relapse in patients previously treated with chemotherapy alone at first relapse: A subanalysis of the DESKTOP III trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5520-5520.	1.6	2
18	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	2.5	12

#	ARTICLE	IF	CITATIONS
19	Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 146-153.	6.3	31
20	Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study. European Journal of Cancer, 2021, 143, 88-100.	2.8	27
21	Curative effect of second curettage for treatment of gestational trophoblastic disease - Results of the Belgian registry for gestational trophoblastic disease. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 257, 95-99.	1.1	3
22	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiotherapy and Oncology, 2021, 154, 327-353.	0.6	96
23	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 153-190.	2.8	99
24	Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients. Cancers, 2021, 13, 1076.	3.7	5
25	Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB-IIIB cervical cancer. International Journal of Gynecological Cancer, 2021, 31, 824-828.	2.5	6
26	Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncology, The, 2021, 22, 609-619.	10.7	186
27	SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.. Journal of Clinical Oncology, 2021, 39, TPS5610-TPS5610.	1.6	6
28	Observational BGOG Study of the Results of Robot-assisted Laparoscopy in 166 Patients with FIGO 2009 Stage IA1-IB1 Cervical Cancer. Journal of Minimally Invasive Gynecology, 2021, 28, 1920-1926.	0.6	1
29	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium. Cancers, 2021, 13, 2613.	3.7	10
30	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 620-631.	10.7	215
31	Health concerns in long-term survivors with ovarian cancer: Results of Expression VI—Carolyn meets HANNA—Holistic Analysis of Long-term survival with Ovarian Cancer—The international NOGGO, ENGOT and GCIG survey.. Journal of Clinical Oncology, 2021, 39, 12023-12023.	1.6	1
32	Lower-Limb Lymphedema after Sentinel Lymph Node Biopsy in Cervical Cancer Patients. Cancers, 2021, 13, 2360.	3.7	15
33	Type of chemotherapy has substantial effects on the immune system in ovarian cancer. Translational Oncology, 2021, 14, 101076.	3.7	11
34	<scp>ESGO</scp>/<scp>ISUOG</scp>/<scp>IOTA</scp>/<scp>ESGE</scp> Consensus Statement on preoperative diagnosis of ovarian tumors. Ultrasound in Obstetrics and Gynecology, 2021, 58, 148-168.	1.7	42
35	Safety and efficiency of performing transvaginal ultrasound-guided tru-cut biopsy for pelvic masses. Gynecologic Oncology, 2021, 161, 845-851.	1.4	7
36	ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours. Facts, Views & Vision in ObGyn, 2021, 13, 107-130.	1.1	7

#	ARTICLE	IF	CITATIONS
37	Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1669-1680.	2.5	5
38	ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 961-982.	2.5	54
39	Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. <i>Annals of Oncology</i> , 2021, 32, 757-765.	1.2	105
40	Immunotherapy in rare ovarian cancer. <i>Current Opinion in Oncology</i> , 2021, 33, 447-456.	2.4	3
41	High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. <i>Genome Medicine</i> , 2021, 13, 111.	8.2	70
42	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. <i>Journal of Clinical Oncology</i> , 2021, 39, 3623-3632.	1.6	69
43	Response to: Correspondence on "ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors" by Thomassin-Nagarra et al. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1396-1397.	2.5	1
44	Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria. <i>Gynecologic Oncology</i> , 2021, 162, 539-545.	1.4	7
45	Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study. <i>Gynecologic Oncology</i> , 2021, 162, 694-701.	1.4	9
46	Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). <i>Gynecologic Oncology</i> , 2021, 163, 237-245.	1.4	30
47	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , 2021, 154, 190-200.	2.8	9
48	Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. <i>European Journal of Cancer</i> , 2021, 157, 415-423.	2.8	18
49	Experience with PlasmaJet [®] in debulking surgery in 87 patients with advanced-stage ovarian cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1109-1114.	1.7	6
50	Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1041-1048.	2.5	1
51	Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 183-194.	2.5	14
52	Concordance Between Tumor and Germline <i>BRCA</i> Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 917-923.	6.3	26
53	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 12-39.	2.5	859
54	Immunological configuration of ovarian carcinoma: features and impact on disease outcome. , 2021, 9, e002873.		30

#	ARTICLE	IF	CITATIONS
55	Peripherally-driven myeloid NFκB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. , 2021, 9, e003609.		24
56	Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancerâ€”A Study of the OVCAD Consortium. Cancers, 2021, 13, 5865.	3.7	3
57	European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 1508-1529.	2.5	13
58	Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer. Cancers, 2021, 13, 5899.	3.7	9
59	Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. New England Journal of Medicine, 2021, 385, 2123-2131.	27.0	144
60	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. Carcinogenesis, 2020, 41, 442-451.	2.8	10
61	The LACC Trial and Minimally Invasive Surgery in Cervical Cancer. Journal of Minimally Invasive Gynecology, 2020, 27, 462-463.	0.6	27
62	Oncologic outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of lymph node positivity; ABRAX (ABandoning RAD hyst in cerviX) Tj ETQq0 0 O2gBT /Ovar10 Tf		
63	A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. Gynecologic Oncology, 2020, 156, 23-31.	1.4	40
64	A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel. Gynecologic Oncology, 2020, 156, 293-300.	1.4	18
65	Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clinical Cancer Research, 2020, 26, 1220-1228.	7.0	77
66	Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors. Gynecologic Oncology, 2020, 159, 811-819.	1.4	8
67	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. European Journal of Cancer, 2020, 139, 59-67.	2.8	12
68	European Network of Gynaecological Oncological Trial Groupsâ€™ requirements for trials between academic groups and industry partners â€” a new Model D for drug and medical device development. International Journal of Gynecological Cancer, 2020, 30, 730-734.	2.5	3
69	Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study. BMJ, The, 2020, 370, m2614.	6.0	54
70	Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial. European Journal of Cancer, 2020, 137, 69-80.	2.8	56
71	Definition and Independent Validation of a Proteomic-Classifer in Ovarian Cancer. Cancers, 2020, 12, 2519.	3.7	3
72	MILO/ENGOT-ov11: Binimetinib Versus Physicianâ€™s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Journal of Clinical Oncology, 2020, 38, 3753-3762.	1.6	82

#	ARTICLE	IF	CITATIONS
73	Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 819-824.	2.5	7
74	Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2). <i>Cancers</i> , 2020, 12, 1115.	3.7	4
75	A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. <i>Cell Research</i> , 2020, 30, 745-762.	12.0	391
76	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	83
77	miR-181a overexpression predicts the poor treatment response and early progression of serous ovarian cancer patients. <i>International Journal of Cancer</i> , 2020, 147, 3560-3573.	5.1	7
78	Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 436-440.	2.5	61
79	Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. <i>Gynecologic Oncology</i> , 2020, 157, 245-251.	1.4	24
80	Second-line lenvatinib in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 575-582.	1.4	53
81	Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study. <i>Cells</i> , 2020, 9, 305.	4.1	22
82	Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models. <i>Stem Cell Reports</i> , 2020, 14, 717-729.	4.8	105
83	A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data. <i>Journal of the National Cancer Institute</i> , 2020, 112, 979-988.	6.3	17
84	European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 3-14.	2.5	39
85	Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 509-514.	2.5	9
86	Para-aortic lymph node surgical staging in locally-advanced cervical cancer: comparison between robotic versus conventional laparoscopy. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 466-472.	2.5	8
87	Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial. , 2020, , .		5
88	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6002-6002.	1.6	75
89	Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6005-6005.	1.6	25
90	Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6095-TPS6095.	1.6	5

#	ARTICLE	IF	CITATIONS
91	Treatment algorithm in patients with ovarian cancer. <i>Facts, Views & Vision in ObGyn</i> , 2020, 12, 227-239.	1.1	2
92	Evaluation of T2-W MR imaging and diffusion-weighted imaging for the early post-treatment local response assessment of patients treated conservatively for cervical cancer: a multicentre study. <i>European Radiology</i> , 2019, 29, 309-318.	4.5	25
93	Joint ENGOT and GOG Foundation requirements for trials with industry partners. <i>Gynecologic Oncology</i> , 2019, 154, 255-258.	1.4	7
94	Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review. <i>Journal of Ovarian Research</i> , 2019, 12, 105.	3.0	25
95	Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer. <i>Anticancer Research</i> , 2019, 39, 5953-5962.	1.1	13
96	Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 186-191.	1.4	54
97	Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancerâ€”A Study of the GANNET53 Consortium. <i>Frontiers in Oncology</i> , 2019, 9, 832.	2.8	23
98	Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1141-1147.	2.5	11
99	Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1273.	4.8	65
100	Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 699-708.	2.5	22
101	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	10.7	68
102	Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer. <i>Neoplasia</i> , 2019, 21, 582-590.	5.3	24
103	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019, 8, 2503-2513.	2.8	6
104	ESMOâ€”ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>Annals of Oncology</i> , 2019, 30, 672-705.	1.2	665
105	ESMOâ€”ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 728-760.	2.5	167
106	Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 537-560.	4.1	19
107	Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. <i>Annals of Oncology</i> , 2019, 30, 1080-1087.	1.2	456
108	Epithelial ovarian cancer. <i>Lancet</i> , The, 2019, 393, 1240-1253.	13.7	1,039

#	ARTICLE	IF	CITATIONS
109	Combining conventional therapy with immunotherapy: A risky business?. European Journal of Cancer, 2019, 113, 41-44.	2.8	25
110	Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. Lancet Oncology, The, 2019, 20, 448-458.	10.7	110
111	Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for Stage IB2-IIB cervical cancer: EORTC55994. , 2019, , .		6
112	EP877â€¦Intestinal (sub)obstruction in ovarian cancer patients: management, complications and survival. , 2019, , .		0
113	Joint ENGOT and GOG Foundation requirements for trials with industry partners. International Journal of Gynecological Cancer, 2019, 29, 1094-1097.	2.5	6
114	Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer. Cancer, 2019, 125, 4594-4597.	4.1	37
115	Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors. International Journal of Gynecological Cancer, 2019, 29, 1381-1388.	2.5	17
116	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2416-2428.	27.0	1,176
117	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. Oncologist, 2019, 24, 165-171.	3.7	23
118	Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. European Journal of Surgical Oncology, 2019, 45, 67-74.	1.0	22
119	First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.. Journal of Clinical Oncology, 2019, 37, 2525-2525.	1.6	14
120	Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage lb2-Ilb cervical cancer, EORTC 55994.. Journal of Clinical Oncology, 2019, 37, 5503-5503.	1.6	68
121	Mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.. Journal of Clinical Oncology, 2019, 37, 5520-5520.	1.6	3
122	First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts).. Journal of Clinical Oncology, 2019, 37, 2521-2521.	1.6	0
123	Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 2018, 29, 1189-1194.	1.2	8
124	Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. Clinical Cancer Research, 2018, 24, 2312-2318.	7.0	51
125	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. Neoplasia, 2018, 20, 280-288.	5.3	23
126	Antiangiogenic therapies in ovarian cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 18-26.	0.5	1

#	ARTICLE	IF	CITATIONS
127	<i>ABCB1</i> Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 277-287.	2.5	10
128	Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3928-3940.	7.0	35
129	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.	6.4	15
130	Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. <i>Annals of Oncology</i> , 2018, 29, 910-916.	1.2	20
131	Breast cancer subtype and survival by parity and time since last birth. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 481-487.	2.5	6
132	Positive DESKTOP and Tian Scores Systems Are Adequate to Predict Optimal (R0) Secondary Debulking Surgery in Ovarian Cancer, But a Negative Score Does Not Preclude Secondary Surgery. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 721-728.	2.5	5
133	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients—A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2018, 149, 371-380.	1.4	11
134	Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 189-196.	2.5	7
135	Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1692-1698.	2.5	18
136	Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. <i>Lancet Oncology</i> , The, 2018, 19, 1680-1687.	10.7	187
137	Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the long term: a randomised trial. <i>Journal of Physiotherapy</i> , 2018, 64, 245-254.	1.7	25
138	Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 842.	3.5	5
139	The genetic landscape of 87 ovarian germ cell tumors. <i>Gynecologic Oncology</i> , 2018, 151, 61-68.	1.4	44
140	Safety and dose modification for patients receiving niraparib. <i>Annals of Oncology</i> , 2018, 29, 1784-1792.	1.2	125
141	Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).. <i>British Journal of Cancer</i> , 2018, 119, 330-338.	6.4	13
142	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.	2.5	9
143	Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. <i>Gynecologic Oncology</i> , 2018, 150, 31-37.	1.4	42
144	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	4.1	3

#	ARTICLE	IF	CITATIONS
145	Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5511-5511.	1.6	45
146	AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancerâ€”Overall survival (OS) results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5518-5518.	1.6	7
147	Ovarian cancer and the immune system. <i>Gynecologic Oncology Reports</i> , 2017, 19, 57-58.	0.6	16
148	Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. <i>Annals of Oncology</i> , 2017, 28, 1842-1848.	1.2	43
149	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. <i>European Journal of Cancer</i> , 2017, 70, 111-121.	2.8	70
150	Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. <i>Oncology Letters</i> , 2017, 13, 4047-4054.	1.8	25
151	Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapyâ€”Innovative Models Prolong Survival (OCTIPS) Consortium. <i>European Journal of Cancer</i> , 2017, 79, 214-225.	2.8	29
152	Neoadjuvant Weekly Paclitaxel-Carboplatin Is Effective in Stage Iâ€”II Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1256-1260.	2.5	14
153	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
154	Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. <i>Annals of Oncology</i> , 2017, 28, 727-732.	1.2	203
155	A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7621-7632.	7.0	31
156	Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. <i>European Journal of Cancer</i> , 2017, 86, 5-14.	2.8	49
157	Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. <i>European Journal of Cancer</i> , 2017, 83, 88-98.	2.8	93
158	A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 258-266.	2.5	35
159	Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. <i>BMC Medicine</i> , 2017, 15, 116.	5.5	44
160	Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses. <i>Clinical Cancer Research</i> , 2017, 23, 2223-2231.	7.0	80
161	Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2213-2222.	7.0	83
162	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.	2.5	3

#	ARTICLE	IF	CITATIONS
163	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. <i>Oncotarget</i> , 2017, 8, 106415-106428.	1.8	42
164	PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5605-TPS5605.	1.6	3
165	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. <i>Oncotarget</i> , 2017, 8, 64670-64684.	1.8	7
166	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	1.9	71
167	mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L,) Tj ETQq1 1 0,784314 rgBT /Over	0,9	5
168	External validation of non-imaging models for predicting distant metastasis in patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 142, 83-88.	1.4	4
169	Statistical controversies in clinical research: the importance of importance. <i>Annals of Oncology</i> , 2016, 27, 1185-1189.	1.2	13
170	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
171	Ovarian cancer in children and adolescents: A rare disease that needs more attention. <i>Maturitas</i> , 2016, 88, 3-8.	2.4	19
172	Evaluation of models to predict lymph node metastasis in endometrial cancer: A multicentre study. <i>European Journal of Cancer</i> , 2016, 61, 52-60.	2.8	27
173	Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study. <i>British Journal of Radiology</i> , 2016, 89, 20160468.	2.2	18
174	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
175	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 2154-2164.	27.0	1,860
176	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3460-3473.	1.6	318
177	Long-term oncological safety of minimally invasive surgery in high-risk endometrial cancer. <i>European Journal of Cancer</i> , 2016, 65, 185-191.	2.8	35
178	Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. <i>Gynecologic Oncology</i> , 2016, 143, 27-34.	1.4	81
179	Combined modality adjuvant therapy for high-risk endometrial cancer. <i>Lancet Oncology</i> , The, 2016, 17, 1029-1030.	10.7	6
180	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	9.4	157

#	ARTICLE	IF	CITATIONS
181	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
182	AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer. <i>BMC Genomics</i> , 2016, 17, 643.	2.8	19
183	Laparoscopic versus robotic-assisted sacrocolpopexy for pelvic organ prolapse: a systematic review. <i>Gynecological Surgery</i> , 2016, 13, 115-123.	0.9	45
184	Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). <i>Journal of Clinical Oncology</i> , 2016, 34, 2516-2525.	1.6	60
185	Sentinel nodes in vulvar cancer: Long-term follow-up of the Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. <i>Gynecologic Oncology</i> , 2016, 140, 8-14.	1.4	226
186	Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 424-437.	1.3	212
187	Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. <i>European Journal of Cancer</i> , 2016, 53, 51-64.	2.8	45
188	A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse. <i>Journal of Clinical Oncology</i> , 2016, 34, 2271-2278.	1.6	114
189	Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. <i>Oncology</i> , 2016, 5, e1111505.	4.6	31
190	Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas. <i>Lancet Oncology</i> , 2016, 17, 273-274.	10.7	9
191	The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients' results from the OVCAD study. <i>Tumor Biology</i> , 2016, 37, 3009-3016.	1.8	23
192	Prospective study evaluating the effect of impaired tamoxifen metabolism on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting. <i>Journal of Clinical Oncology</i> , 2016, 34, 523-523.	1.6	4
193	Tenckhoff tunneled peritoneal catheter placement in the palliative treatment of malignant ascites: technical results and overall clinical outcome. <i>Radiology and Oncology</i> , 2016, 50, 197-203.	1.7	26
194	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	1.8	5
195	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	1.8	13
196	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368.	1.8	29
197	The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer. <i>Anticancer Research</i> , 2016, 36, 5781-5792.	1.1	14
198	In Vitro Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol. <i>Anticancer Research</i> , 2016, 36, 5793-5802.	1.1	11

#	ARTICLE	IF	CITATIONS
199	New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes. Facts, Views & Vision in ObGyn, 2016, 8, 161-167.	1.1	1
200	Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. Anticancer Research, 2016, 36, 1015-22.	1.1	4
201	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
202	The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer. , 2015, 3, 57.		17
203	Diagnosing adnexal tumours before surgery: a critical appraisal of recent evidence. The Obstetrician and Gynaecologist, 2015, 17, 163-171.	0.4	1
204	European Network of Gynaecological Oncological Trial Groups™ Requirements for Trials Between Academic Groups and Industry Partners™ First Update 2015. International Journal of Gynecological Cancer, 2015, 25, 1328-1330.	2.5	22
205	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
206	Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women™s Cancers. PLoS ONE, 2015, 10, e0143178.	2.5	14
207	Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecologic Oncology, 2015, 138, 18-23.	1.4	64
208	Para-aortic lymph node metastases in locally advanced cervical cancer: Comparison between surgical staging and imaging. Gynecologic Oncology, 2015, 138, 299-303.	1.4	50
209	Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Targeted Oncology, 2015, 10, 583-596.	3.6	23
210	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Medicine, 2015, 7, 108.	8.2	138
211	Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial. Gynecologic Oncology, 2015, 136, 37-42.	1.4	29
212	Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. Gynecologic Oncology, 2015, 136, 18-24.	1.4	39
213	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
214	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
215	Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. Gynecologic Oncology, 2015, 139, 118-126.	1.4	52
216	Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2015, 113, 817-826.	6.4	111

#	ARTICLE	IF	CITATIONS
217	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015, 21, 5264-5276.	7.0	33
218	Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer. <i>Gynecologic Oncology</i> , 2015, 139, 447-451.	1.4	45
219	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	1.4	15
220	Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 2.	2.4	33
221	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015, 6, 8234.	12.8	63
222	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	2.8	24
223	Morcellation of uterine leiomyomas: a plea for patient triage. <i>Lancet Oncology</i> , The, 2015, 16, 1454-1456.	10.7	22
224	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	2.9	68
225	Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group. <i>Gynecologic Oncology</i> , 2015, 138, 278-284.	1.4	19
226	Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4293-4300.	1.6	87
227	Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5503-5503.	1.6	8
228	Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5504-5504.	1.6	3
229	Randomized phase III study comparing paclitaxel-carboplatin with paclitaxel-carboplatin in patients with recurrent platinum-sensitive epithelial ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5517-5517.	1.6	9
230	First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5537-5537.	1.6	12
231	Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5547-5547.	1.6	2
232	Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5549-5549.	1.6	5
233	Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5550-5550.	1.6	9
234	Preliminary phase II results of selinexor, an oral selective inhibitor of nuclear export in patients with heavily pretreated gynecological cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5565-5565.	1.6	4

#	ARTICLE	IF	CITATIONS
235	EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC).. Journal of Clinical Oncology, 2015, 33, TPS5605-TPS5605.	1.6	5
236	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
237	Bevacizumab (BEV) with or after chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (PROC): Exploratory analyses of the AURELIA trial.. Journal of Clinical Oncology, 2015, 33, 5551-5551.	1.6	0
238	Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. Journal of Clinical Oncology, 2015, 33, 5578-5578.	1.6	0
239	Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors. Facts, Views & Vision in ObGyn, 2015, 7, 32-41.	1.1	21
240	Immunological parameters as a new lead in the diagnosis of ovarian cancer. Facts, Views & Vision in ObGyn, 2015, 7, 67-72.	1.1	3
241	A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?. Facts, Views & Vision in ObGyn, 2015, 7, 73-8.	1.1	3
242	A Core Invasiveness Gene Signature Reflects Epithelial-to-Mesenchymal Transition but Not Metastatic Potential in Breast Cancer Cell Lines and Tissue Samples. PLoS ONE, 2014, 9, e89262.	2.5	13
243	HIF1 α ; is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium. OncoTargets and Therapy, 2014, 7, 1563.	2.0	18
244	Reactive Nodular Fibrous Pseudotumor: Case Report and Review of the Literature. Case Reports in Obstetrics and Gynecology, 2014, 2014, 1-4.	0.3	2
245	Variation in NF- κ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	2.5	13
246	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. Gynecologic Oncology, 2014, 135, 415-422.	1.4	38
247	Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. European Radiology, 2014, 24, 889-901.	4.5	189
248	Novel therapies, including enzastaurin, in the treatment of ovarian cancer. Expert Opinion on Investigational Drugs, 2014, 23, 579-598.	4.1	6
249	A phase Ib, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. European Journal of Cancer, 2014, 50, 2408-2416.	2.8	21
250	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2014, 15, 799-808.	10.7	279
251	Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) â a study of the TOC Consortium. Journal of Ovarian Research, 2014, 7, 49.	3.0	21
252	Prognostic implications of lobular breast cancer histology: New insights from a single hospital cross-sectional study and SEER data. Breast, 2014, 23, 371-377.	2.2	10

#	ARTICLE	IF	CITATIONS
253	Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. <i>British Journal of Cancer</i> , 2014, 111, 680-688.	6.4	98
254	Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1302-1308.	1.6	1,240
255	Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients – A study of the OVCAD consortium. <i>European Journal of Cancer</i> , 2014, 50, 99-110.	2.8	53
256	BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). <i>European Journal of Cancer</i> , 2014, 50, 2090-2098.	2.8	75
257	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 852-861.	10.7	1,237
258	Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11061-11061.	1.6	2
259	Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2599-2599.	1.6	1
260	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. <i>Gynecologic Oncology</i> , 2013, 131, 8-14.	1.4	55
261	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	21.4	326
262	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
263	Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?. <i>Gynecologic Oncology</i> , 2013, 128, 6-11.	1.4	105
264	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance – A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013, 128, 15-21.	1.4	107
265	Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer – a study by the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013, 128, 38-43.	1.4	22
266	The –Leuven–paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study. <i>Gynecologic Oncology</i> , 2013, 128, 34-37.	1.4	9
267	Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (<sc>IOTA</sc>) studies. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 41, 9-20.	1.7	153
268	PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 694-700.	1.4	54
269	A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, 145-152.	1.2	74
270	Dendritic cell-based immunotherapy in ovarian cancer. <i>Oncolmmunology</i> , 2013, 2, e27059.	4.6	10

#	ARTICLE	IF	CITATIONS
271	The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. <i>Epigenetics</i> , 2013, 8, 1226-1235.	2.7	19
272	Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. <i>Annals of Oncology</i> , 2013, 24, 350-355.	1.2	35
273	Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers. <i>Annals of Oncology</i> , 2013, 24, 1847-1852.	1.2	34
274	Multi-center experience of robot-assisted laparoscopic para-aortic lymphadenectomy for staging of locally advanced cervical carcinoma. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2013, 92, 895-901.	2.8	23
275	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
276	Roadmap for the European Network of Gynaecological Trial Groups (ENGOT) Trials. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1339-1343.	2.5	10
277	Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium "OVCAD. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 268-275.	2.5	46
278	Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first-line chemotherapy for advanced epithelial ovarian cancer (EOC): A GCIIG study of NCIC CTG, EORTC-GCG, and GEICO. <i>Journal of Clinical Oncology</i> , 2013, 31, 5502-5502.	1.6	2
279	An analysis of preoperatively HE4 and CA125 in matched samples of patients (pts) with benign disease and borderline ovarian tumors (BOT) with and without invasive implants (InvImp). <i>Journal of Clinical Oncology</i> , 2013, 31, e22102-e22102.	1.6	0
280	Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. <i>Annals of Oncology</i> , 2012, 23, 2578-2584.	1.2	46
281	First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC) a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. <i>Annals of Oncology</i> , 2012, 23, 2613-2619.	1.2	26
282	Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. <i>European Journal of Cancer</i> , 2012, 48, 1649-1656.	2.8	104
283	Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer. <i>European Journal of Cancer</i> , 2012, 48, 1332-1340.	2.8	18
284	Triaging women with ovarian masses for surgery: observational diagnostic study to compare RCOG guidelines with an International Ovarian Tumour Analysis (IOTA) group protocol. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 662-671.	2.3	49
285	Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium. <i>Cancer Science</i> , 2012, 103, 1334-1341.	3.9	59
286	Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval \geq 12 months) subpopulation of OVA-301 phase III randomized trial. <i>Annals of Oncology</i> , 2011, 22, 39-48.	1.2	146
287	Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: An analysis of 163 patients. <i>European Journal of Cancer</i> , 2011, 47, 191-198.	2.8	11
288	Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. <i>European Journal of Cancer</i> , 2011, 47, S88-S92.	2.8	106

#	ARTICLE	IF	CITATIONS
289	Should we screen for endometrial cancer?. <i>Lancet Oncology</i> , The, 2011, 12, 4-5.	10.7	20
290	Gynecologic Cancers in Pregnancy: Guidelines of an International Consensus Meeting. , 2011, , 209-227.		1
291	Performance of the American College of Obstetricians and Gynecologists' Ovarian Tumor Referral Guidelines With a Multivariate Index Assay. <i>Obstetrics and Gynecology</i> , 2011, 118, 1179-1181.	2.4	9
292	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. <i>Nature Genetics</i> , 2011, 43, 451-454.	21.4	141
293	HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. <i>British Journal of Cancer</i> , 2011, 104, 863-870.	6.4	270
294	OC21.02: Selection of women with an ovarian tumor for surgery in specialist centers: a comparison of two triaging protocols. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 39-39.	1.7	0
295	OC21.04: A prediction model to distinguish between benign, borderline, stage I invasive, higher stage invasive, and metastatic adnexal tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 40-40.	1.7	0
296	Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. <i>Annals of Oncology</i> , 2011, 22, 49-58.	1.2	53
297	Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). <i>International Journal of Gynecological Cancer</i> , 2011, 21, 419-423.	2.5	500
298	A Novel Approach to Predict the Likelihood of Specific Ovarian Tumor Pathology Based on Serum CA-125: A Multicenter Observational Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2420-2428.	2.5	32
299	Reply: The performance of the risk of ovarian malignancy algorithm. <i>British Journal of Cancer</i> , 2011, 105, 187-188.	6.4	0
300	Neoadjuvant Chemotherapy Is the Better Treatment Option in Some Patients With Stage IIIc to IV Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4076-4078.	1.6	59
301	Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 772-780.	2.5	52
302	The Role of Diaphragmatic Surgery During Interval Debulking After Neoadjuvant Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 542-551.	2.5	9
303	European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 476-478.	2.5	38
304	Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. <i>Ultrasound in Obstetrics and Gynecology</i> , 2010, 36, 226-234.	1.7	154
305	OC23.01: New logistic regression model to predict ovarian malignancy in cases for which simple ultrasound rules are not applicable. <i>Ultrasound in Obstetrics and Gynecology</i> , 2010, 36, 41-42.	1.7	0
306	Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 116, 489-496.	1.4	31

#	ARTICLE	IF	CITATIONS
307	Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?. <i>Gynecologic Oncology</i> , 2010, 119, 1-2.	1.4	30
308	Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. <i>Journal of Clinical Oncology</i> , 2010, 28, 3323-3329.	1.6	500
309	Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. <i>BMJ: British Medical Journal</i> , 2010, 341, c6839-c6839.	2.3	336
310	Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. <i>Lancet Oncology</i> , The, 2010, 11, 646-652.	10.7	228
311	Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 943-953.	27.0	2,066
312	Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50 5 1511-1516.	1.2	76
313	A scoring system to differentiate malignant from benign masses in specific ultrasound-based subgroups of adnexal tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 33, 92-101.	1.7	36
314	Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 345-354.	1.7	57
315	OC05.01: Predicting ovarian malignancy if simple rules are not applicable. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 7-7.	1.7	0
316	EORTC's GCG process quality indicators for ovarian cancer surgery. <i>European Journal of Cancer</i> , 2009, 45, 517-526.	2.8	48
317	A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. <i>European Journal of Cancer</i> , 2009, 45, 1415-1423.	2.8	52
318	Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. <i>European Journal of Cancer</i> , 2009, 45, 2324-2332.	2.8	97
319	Gynecologic Cancer Intergroup (GCI) proposals for changes of the current FIGO staging system. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2009, 143, 69-74.	1.1	69
320	Screening for ovarian carcinoma: not quite there yet. <i>Lancet Oncology</i> , The, 2009, 10, 308-309.	10.7	11
321	Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer: Results From a Safety Lead-in Study. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1505-1510.	2.5	7
322	Clear Cell Carcinoma Compared to Serous Carcinoma in Early Ovarian Cancer: Same Prognosis in a Large Randomized Trial. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 88-93.	2.5	56
323	Role of Diaphragmatic Surgery in 69 Patients With Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 481-481.	2.5	11
324	Using Bayesian neural networks with ARD input selection to detect malignant ovarian masses prior to surgery. <i>Neural Computing and Applications</i> , 2008, 17, 489-500.	5.6	9

#	ARTICLE	IF	CITATIONS
325	Robotic retroperitoneal lower para-aortic lymphadenectomy in cervical carcinoma: First report on the technique used in 5 patients. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2008, 87, 783-787.	2.8	70
326	Simple ultrasound-based rules for the diagnosis of ovarian cancer. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 31, 681-690.	1.7	435
327	OC152: Prevalence of cancer and optimal cut-off levels for mathematical models to distinguish between benign and malignant adnexal masses. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 32, 292-293.	1.7	0
328	OP17.01: Prospective comparison of one-step and two-step models for the classification of adnexal masses as benign or malignant. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 32, 368-368.	1.7	0
329	Role of diaphragmatic surgery in 69 patients with ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 363-368.	2.5	35
330	Laparoscopic para-aortic lymphadenectomy and positron emission tomography scan as staging procedures in patients with cervical carcinoma stage IB2-III B. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 723-729.	2.5	40
331	Timing of debulking surgery in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 11-19.	2.5	79
332	The Addition of 4% Oxygen to the CO2 Pneumoperitoneum Does Not Decrease Dramatically Port Site Metastases. <i>Journal of Minimally Invasive Gynecology</i> , 2008, 15, 700-703.	0.6	8
333	Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 884-889.	1.6	684
334	Intraperitoneal Chemotherapy in Patients with Advanced Ovarian Cancer: The Con View. <i>Oncologist</i> , 2008, 13, 410-414.	3.7	23
335	Value of Positron Emission Tomography of the Para-Aortic Lymph Nodes in Cervical Carcinoma Stage IB2-III B. <i>Journal of Clinical Oncology</i> , 2008, 26, 5654-5655.	1.6	12
336	External Validation of Mathematical Models to Distinguish Between Benign and Malignant Adnexal Tumors: A Multicenter Study by the International Ovarian Tumor Analysis Group. <i>Clinical Cancer Research</i> , 2007, 13, 4440-4447.	7.0	65
337	Improving outcome in the first-line management of advanced ovarian cancer. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 23-28.	2.2	3
338	Management of Borderline Ovarian Neoplasms. <i>Journal of Clinical Oncology</i> , 2007, 25, 2928-2937.	1.6	174
339	A new prognostic model for FIGO stage 1 epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 104, 607-611.	1.4	29
340	The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 106, 354-361.	1.4	37
341	Preoperative diagnosis of ovarian tumors using Bayesian kernel-based methods. <i>Ultrasound in Obstetrics and Gynecology</i> , 2007, 29, 496-504.	1.7	36
342	The management of borderline tumours of the ovary. <i>Current Opinion in Oncology</i> , 2006, 18, 488-493.	2.4	32

#	ARTICLE	IF	CITATIONS
343	Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 524-526.	2.5	8
344	Ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 159-179.	4.4	186
345	Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 102, 415-417.	1.4	20
346	Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental. <i>Journal of Clinical Oncology</i> , 2006, 24, 4528-4530.	1.6	83
347	Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. <i>Annals of Oncology</i> , 2006, 17, 200-204.	1.2	63
348	Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 776-779.	2.5	113
349	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. <i>Cancer</i> , 2005, 104, 236-239.	4.1	154
350	Chemotherapy for cervical cancer. <i>European Clinics in Obstetrics and Gynaecology</i> , 2005, 1, 143-150.	0.4	2
351	Clinicopathologic markers of uterine leiomyosarcoma originating from smooth muscle tumors of low malignancy. <i>European Clinics in Obstetrics and Gynaecology</i> , 2005, 1, 164-170.	0.4	0
352	2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC) Tj ETQq0 0 0 rgEE/Overlost10 Tf 50		
353	Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. <i>Annals of Oncology</i> , 2005, 16, viii13-viii19.	1.2	37
354	Logistic Regression Model to Distinguish Between the Benign and Malignant Adnexal Mass Before Surgery: A Multicenter Study by the International Ovarian Tumor Analysis Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 8794-8801.	1.6	396
355	Report of an Early Stopped Randomized Trial Comparing Cisplatin vs. Cisplatin/Ifosfamide/5-Fluorouracil in Recurrent Cervical Cancer. <i>Gynecologic and Obstetric Investigation</i> , 2005, 59, 126-129.	1.6	18
356	A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. <i>Cancer Treatment Reviews</i> , 2005, 31, 274-282.	7.7	27
357	Neoadjuvant chemotherapy for ovarian cancer. <i>Oncology</i> , 2005, 19, 1615-22; discussion 1623-30.	0.5	18
358	A possible role of the cytochrome P450c17 \pm gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2004, 83, 234-239.	2.8	12
359	Letter to the Editor. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 396-396.	2.5	0
360	Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. <i>British Journal of Cancer</i> , 2004, 90, S11-S14.	6.4	33

#	ARTICLE	IF	CITATIONS
361	Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2004, 18, 349-371.	2.8	257
362	Endocrine treatment and prevention of breast and gynaecological cancers. European Journal of Cancer, Supplement, 2004, 2, 1-14.	2.2	0
363	Role of Surgery in Ovarian Cancer: An Update. Acta Chirurgica Belgica, 2004, 104, 246-256.	0.4	23
364	Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer. Journal of Clinical Oncology, 2004, 22, 5058-5058.	1.6	9
365	Postmenopausal Women who Progress on Fulvestrant ('Faslodex') Remain Sensitive to Further Endocrine Therapy. Breast Cancer Research and Treatment, 2003, 79, 207-211.	2.5	60
366	Preoperative prediction of malignancy of ovarian tumors using least squares support vector machines. Artificial Intelligence in Medicine, 2003, 28, 281-306.	6.5	71
367	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. Cancer, 2003, 98, 229-238.	4.1	305
368	First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. International Journal of Gynecological Cancer, 2003, 13, 172-177.	2.5	44
369	Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. Journal of the National Cancer Institute, 2003, 95, 113-125.	6.3	597
370	Controversies in surgery in ovarian cancer " what is its real role?. European Journal of Cancer, Supplement, 2003, 1, 115-125.	2.2	4
371	RESPONSE: Re: Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Cancer. Journal of the National Cancer Institute, 2003, 95, 1170-1171.	6.3	2
372	Positron Emission Tomography with FDG in the Detection of Peritoneal and Retroperitoneal Metastases of Ovarian Cancer. Gynecologic and Obstetric Investigation, 2003, 55, 130-134.	1.6	66
373	Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Annals of Oncology, 2003, 14, 1494-1500.	1.2	55
374	Treatment of patients with early epithelial ovarian cancer. Current Opinion in Oncology, 2003, 15, 452-455.	2.4	22
375	INTRAPERITONEAL (IP) CISPLATIN (P) VERSUS NO FURTHER TREATMENT: 8 YEAR-RESULTS OF AN EORTCCCGG RANDOMIZED PHASE III STUDY IN OVARIAN CANCER (O.C.) PATIENTS (PTS) WITH A PATHOLOGICALLY COMPLETE REMISSION (PCR) AFTER P-BASED INDUCTION CHEMOTHERAPY (CT) AND CYTOREDUCTIVE SURGERY. International Journal of Gynecological Cancer, 2003, 13, 8.4-8.	2.5	3
376	Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment. Journal of Clinical Oncology, 2002, 20, 3396-3403.	1.6	626
377	Endocrine treatment and prevention of breast and gynaecological cancers. European Journal of Cancer, 2002, 38, 1-11.	2.8	4
378	Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women. European Journal of Cancer, 2002, 38, 57-58.	2.8	58

#	ARTICLE	IF	CITATIONS
379	Laparoscopic lower para-aortic staging lymphadenectomy in stage IB2, II, and III cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2002, 12, 22-26.	2.5	78
380	Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. <i>Lancet, The</i> , 2001, 357, 176-182.	13.7	598
381	Cumulative dosage effect of aRAD511/HMGA2 fusion and RAD511 loss in a case of pseudo-Meigs' syndrome. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 324-329.	2.8	12
382	To the Editor. <i>Gynecologic Oncology</i> , 2001, 83, 166-167.	1.4	8
383	Prognostic factors in stage I ovarian carcinoma. <i>Verhandelingen - Koninklijke Academie Voor Geneeskunde Van België</i> , 2001, 63, 257-71; discussion 272-6.	0.2	4
384	Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. <i>Annals of Oncology</i> , 2000, 11, 281-288.	1.2	95
385	Interval debulking surgery: An alternative for primary surgical debulking?. <i>Journal of Surgical Oncology</i> , 2000, 19, 49-53.	1.4	33
386	Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group. <i>Ultrasound in Obstetrics and Gynecology</i> , 2000, 16, 500-505.	1.7	747
387	Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 4038-4044.	1.6	57
388	Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. <i>European Journal of Cancer</i> , 2000, 36, 84-85.	2.8	29
389	Interval debulking surgery: An alternative for primary surgical debulking?. <i>Journal of Surgical Oncology</i> , 2000, 19, 49-53.	1.4	4
390	Laparoscopy in gynaecologic oncology: a review. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 31, 15-26.	4.4	6
391	Advanced epithelial ovarian cancer: 1998 consensus statements. <i>Annals of Oncology</i> , 1999, 10, 87-92.	1.2	146
392	Surgery during chemotherapy and at relapse of ovarian cancer. <i>Annals of Oncology</i> , 1999, 10, 3-7.	1.2	32
393	Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients. <i>Gynecologic Oncology</i> , 1998, 71, 431-436.	1.4	355
394	The Feasibility of Open Laparoscopy in Gynecologic Oncologic Patients. <i>Gynecologic Oncology</i> , 1997, 66, 138-140.	1.4	25
395	Bayesian networks in ovarian cancer diagnosis: potentials and limitations. , 0, , .		16
396	Using artificial neural networks to predict malignancy of ovarian tumors. , 0, , .		7